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INTRODUCTION 
Osteoprotegerin (OPG) and receptor activator of nuclear factor-κB ligand (RANKL), 
two members of the tumor necrosis factor receptor super family, are essential in the regulation 
of bone resorption. In addition to being a key regulator of osteoclastogenesis, the 
OPG/RANKL/RANK system is reported as being a significant mediator between factors such 
as estradiol, testosterone, parathyroid hormone, vitamin D, and bone turnover. Data on OPG 
and RANKL levels in healthy men is accumulating. Nonetheless, based on published data, it 
may well be generalized that the association between OPG/RANKL and its predictors is 
lacking consensus. Furthermore, the association of cystatin C with OPG and RANKL has 
only been limitedly investigated in the healthy, where no significant correlation was found. 
According to literature data, the role of cystatin C in the regulation of bone metabolism is 
largely expected to be clarified. 
Nonetheless, in-vitro studies have implied that cystatin C is a cysteine proteinase 
inhibitor that decreases osteoclastogenesis by interfering at a late stage of pre-osteoclast 
differentiation. Additionally, cystatin C possesses the advantage of being independent of 
gender, muscle mass and age; and consequently may qualify better than creatinine as a 
surrogate marker of renal function in investigating the role of decreased protein clearance as a 
potential cause of age-related OPG elevation. 
We determined serum OPG and sRANKL levels and examined its relationship with age, 
cystatin C, biochemical markers of bone turnover (osteocalcin, C-terminal telopeptides of 
type-I collagen, procollagen type 1 amino-terminal propeptide, 25-hydroxyvitamin D, 
parathyroid hormone), sex hormones (total 17β-estradiol, total testosterone) and bone mineral 
density in randomly selected ambulatory men belonging to the HunMen cohort.  
The role of vitamin D in regulating circulating levels of calcium and phosphorus to 
ensure normal bone mineralization is well known. Emerging evidence correlates insufficient 
levels of vitamin D to an increased risk of developing non-skeletal pathologies: 
cardiovascular diseases, hypertension, cancer, diabetes, multiple sclerosis, rheumatoid 
arthritis, infectious diseases. Maintaining sufficient vitamin D levels is therefore key to 
maintain good general health. Low 25-hydroxyvitamin D (25OHD) levels are associated with 
poor skeletal and extra-skeletal health. Trials of vitamin D supplementation and the Institute 
of Medicine (IOM) systematic review advocate maintaining the serum 25OHD concentration 
between 50 and 100 nmol/L, whereas the Endocrine Society and several others suggest that a 
minimum level of 75 nmol/L is necessary in older adults to minimize the risk of falls and 
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fracture. The optimal serum 25OHD concentrations for extra-skeletal health are evolving but 
appear to be above 75 nmol/L.  
As such, development of robust healthcare policy to improve vitamin D sufficiency is 
critical and is primarily based on vitamin D data achieved from measurement of total 25OHD. 
The gold standard method for vitamin D metabolite testing is the liquid chromatography 
tandem-mass spectrometry (LC-MS/MS) technique. Nonetheless, vitamin D sufficiency is 
estimated by determining 25OHD concentrations and although there is abundance of data on 
vitamin D levels, standardization of 25OHD values is still a challenge. Lately, the Vitamin D 
Standardization Program (VDSP) has delineated protocols for standardizing existing 25OHD 
data from national surveys around the world. In short, the VDSP suggests identifying a batch 
of samples from the sample pool used primarily to determine 25OHD in the given survey, get 
the 25OHD measurements done in the selected batch using the National Institute for 
Standards and Technology (NIST) and Ghent University reference measurement procedures 
(RMP) and use the results attained, as such, to correct the originally measured 25OHD values 
of the sample pool. This approach is well defined but the reference measurement procedure 
requires special equipment and expertise that are available mainly at specialized laboratories, 
furthermore, the financial aspect may also limit its utility. Additionally, from a practical point 
of view, the VDSP approach does not suffice in allowing the correction of 25OHD results 
generated on a daily basis in routine diagnostic laboratories.  
The Vitamin D External Quality Assessment Scheme (DEQAS) survey is an 
international external quality assurance (EQA) survey with more than a thousand participating 
laboratories and encompassing all currently available commercial platforms for 25OHD 
measurements. In each DEQAS survey (four per year), five samples are dispatched by regular 
post at ambient temperature for evaluation by the participating laboratory. In a given survey 
report, percentage bias from All Laboratory Trimmed Mean (ALTM) is reported for the total 
25OHD measurement results of the five samples measured by the participating laboratory. As 
of April 2013, DEQAS also reports values assigned for each sample by the RMP of the NIST, 
allowing participating laboratories to evaluate the accuracy of their own results by comparing 
them to the NIST target values. 
We used DEQAS data to formulate a master formula in order to standardize 25OHD 
values from the HunMen cohort.   
3 
 
AIMS OF THE THESIS 
Our study is based on the previously published HunMen study, which involved 
randomly selected healthy men over 50 years of age from Debrecen, from September 2009 to 
September 2010 to characterize the prevalence and seasonal variation of hypovitaminosis D 
and its relationship to bone metabolism. 
Assessment of factors influencing osteoprotegerin levels 
Int the first phase of our work we aimed to evaluate serum osteoprotegerin and soluble 
receptor activator of nuclear factor κB ligand levels and examined its relationship with age, 
cystatin C, biochemical markers of bone turnover (osteocalcin, C-terminal telopeptides of 
type-I collagen, procollagen type 1 amino-terminal propeptide, 25-hydroxyvitamin D, 
parathyroid hormone), sex hormones (total 17β-estradiol, total testosterone) and bone mineral 
density in randomly selected ambulatory men belonging to the HunMen cohort.  
Standardizing 25-hydroxyvitamin D data from the HunMen cohort 
In the second phase of our work we aimed to standardize total 25OHD values of the 
HunMen cohort. Since there was a switch in methodology at our routine laboratory from 
high-pressure liquid chromatography (HPLC) to chemiluminescence immunoassay (CLIA), 
the original 25OHD values were reanalysed using DiaSorin LIAISON
®
 25OHD total CLIA 
methodology. We applied our approach for standardization by correction of the measured 
25OHD values using the linear regression equation derived from the analysis of relationship 
between total 25OHD values measured by the current methodology used by the laboratory 
and the NIST total target values reported by the DEQAS for all 5 of the DEQAS samples in a 
given survey. 
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MATERIALS AND METHODS 
Study subjects 
The fasting serum samples (n = 194) for OPG and soluble RANKL determinations 
belonged to participants in the HunMen cross-sectional, observational study. Briefly the 
HunMen study was a local initiative to evaluate the bone health of randomly selected healthy 
men. Men residing in Debrecen, Hungary were invited to participate in the study from 
September 2009 to September 2010. During this period, a total of 229 randomly selected 
volunteers agreed to participate. Permission was received from the local ethics committee, 
after conception of the study design, and study procedures were carried out following receipt 
of written informed consent, volunteers not confirming to the inclusion and/or confirming to 
the exclusion criteria (n=3) were excluded from the final statistical analysis. Public attention 
to the initiative was achieved by placing posters summarizing the main aspects of the survey 
at general medical dispensaries. Detailed medical history was collected, and blood sampling 
was done after overnight fasting. Inclusion criteria were over 50 years of age, male, 
ambulatory, community dwelling, and generally regarded as healthy. Exclusion criteria were 
known prevalent metabolic bone disease, liver or renal disease (values ≥2× upper limit of 
normal (ULN) for total bilirubin, aspartate aminotransferase, alanine aminotransferase, 
gamma-glutamyl transpeptidase, alkaline phosphatase, lactate dehydrogenase, cholinesterase, 
urea, creatinine, and uric acid resulted in exclusion), and use of medication influencing bone 
metabolism (excluding calcium and vitamin D supplementation). 
Study procedures 
Serum total OPG and sRANKL were measured using enzyme immunoassays 
(Biomedica Gruppe, Biomedica Medizinprodukte GmbH & Co KG, Wein, Austria). The OPG 
assay, that detects monomeric dimeric and ligand bound OPG, uses a monoclonal mouse anti-
OPG antibody as capture antibody and a biotin-labeled goat polyclonal antibody for detection. 
The sRANKL assay, that detects soluble, uncomplexed human RANKL, uses human 
recombinant OPG for capture and a biotin-labeled goat polyclonal antibody for detection.  
Serum 25-hydroxyvitamin D was analyzed by the automated LIAISON
® 
DiaSorin 
total 25OHD chemiluminescence immunoassay (DiaSorin Inc., Stillwater, MN, USA). 
The LIAISON
®
 25OHD-Vitamin assay is a direct competitive chemiluminescence 
immunoassay for quantitative determination of total 25OHD in serum. During the first 
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incubation, 25OHD is dissociated from its binding protein and binds to the specific antibody 
on the solid phase. After 10 minutes the tracer, (vitamin D linked to an isoluminol derivative) 
is added. After a second 10 minute incubation, the unbound material is removed with a wash 
cycle. Subsequently, the starter reagents are added to initiate a flash chemiluminescent 
reaction. The light signal is measured by photomultiplier as relative light units (RLU) and is 
inversely proportional to the concentration of 25OHD present in calibrators, controls, or 
samples. 
Serum 17β-estradiol (E2), testosterone (T), parathyroid hormone (PTH), osteocalcin 
(OC), C-terminal telopeptides of type-I collagen (CTx), procollagen type 1 amino-terminal 
propeptide (PINP), sex hormone binding globulin (SHBG) were measured using 
electrochemiluminiscence immunoassay (ECLIA; Roche MODULAR E170 Diagnostics 
GmbH, Mannheim, Germany). 
The Elecsys Estradiol III assay employs a competitive test principle using two 
monoclonal antibodies specifically directed against 17β-estradiol. Endogenous estradiol 
released from the sample by mesterolone competes with the added estradiol derivative labeled 
with a ruthenium complex for the binding sites on the biotinylated antibody. 
The Elecsys Testosterone II assay is based on a competitive test principle using a high 
affinity monoclonal antibody (sheep) specifically directed against testosterone. Endogenous 
testosterone released from the sample by 2-bromoestradiol competes with the added 
testosterone derivative labeled with a ruthenium complex for the binding sites on the 
biotinylated antibody. 
The Elecsys SHBG assay is an one-step sandwich immunoassay, based ont he use of 
two mouse monoclonal antibodies and ont the streptavidin-biotin technology. The first 
antibody is biotinylated and used as a capture antibody that bindss to streptavidin-coated 
microparticles. The second antibody, covalently linked with ruthenium, is used for detection. 
The free estradiol index (FEI) and free testosterone index (FTI) was calculated as the total 
17β-estradiol to SHBG ratio and total testosterone to SHBG ratio, respectively. 
The Elecsys assay for determining intact PTH employs a sandwich test principle in 
which a biotinylated monoclonal antibody reacts with the N-terminal fragment (1-37) and a 
monoclonal antibody labeled with a ruthenium complex reacts with the C-terminal fragment 
(38-84). 
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The Elecsys N-MID osteocalcin assay utilizes two monoclonal antibodies, one specific 
for epitopes on the N-MID OC fragment and the other specific for the N terminal OC 
fragment, and therefore detects the intact OC as well as the N-MID fragment. 
Beta-CrossLaps assay a 2-site immunometric (sandwich) assay using 
electrochemiluminescence detection. Patient specimen, biotinylated monoclonal beta-
CrossLaps-specific antibody, and monoclonal beta-CrossLaps-specific antibody labeled with 
ruthenium react to form a complex. Streptavidin-coated microparticles act as the solid phase 
to which the complex binds. Voltage is applied to the electrode, inducing a chemiluminescent 
emission from the ruthenium, which is then measured against a calibration curve to determine 
the amount of beta-CrossLaps in the patient specimen. This assay is specific for crosslinked 
isomerized type I collagen fragments, independent of the nature of the crosslink. The assay 
specificity is guaranteed through the use of 2 monoclonal antibodies, each recognizing linear 
beta-8AA octapeptides. The assay, therefore, quantifies all type I collagen degradation 
fragments that contain the isomerized octapeptide beta-8AA twice (beta-CTx). 
The Elecsys procollagen type 1 amino-terminal propeptide assay uses the sandwich 
principle in which P1NP-specific, biotinylated monoclonal antibodies reacts with the P1NP-
specific, ruthenium-complexed monoclonal antibodies.  
Cystatin C was measured with BN ProSpec analyzer using particle-enhanced 
nephelometric immunoassay (Siemens Healthcare Diagnostics Products GmbH, Marburg, 
Germany). Polystyrene particles coated with specific antibodies to human cystatin C are 
aggregated when mixed with samples containing human cystatin C. These aggregates scatter a 
beam of light passed through the sample. The intensity of the scattered light is proportional to 
the concentration of the respective protein int he sample. The result is evaluated by 
comparison with a standard of known concentration. 
Serum creatinine was measured using the Creatinine Jaffé 2nd generation 
(compensated) test on the cobas c 111 system (Roche Diagnostics GmbH, Mannheim, 
Germany). The 4-variable modification of diet in renal disease (MDRD) study equation was 
used for calculating eGFR. Additionally, eGFR was also calculated using the chronic kidney 
disease epidemiology collaboration (CKD-EPI) cystatin C and CKD-EPI creatinine-cystatin C 
equations. 
Characterization of DEQAS samples 
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The DEQAS survey is an international external quality assurance survey with more 
than a thousand participating laboratories and encompassing all currently available 
commercial platforms for 25OHD measurements. In each DEQAS survey (four per year), five 
samples are dispatched by regular post at ambient temperature for evaluation by the 
participating laboratory. The results are returned online and, after the submission deadline, a 
report is made available that can be downloaded from the DEQAS website. In a given survey 
report, percentage bias from ALTM is reported for the total 25OHD measurement results of 
the five samples measured by the participating laboratory. Submitted results are ranked in 
ascending order and the highest 5% and the lowest 5% (10% in total) are removed. The 
arithmetic mean of the remaining results is the ALTM. The ALTM has been reported to be 
very similar to the NIST target value measured for each sample using the NIST RMP. As of 
April 2013, DEQAS also reports values assigned for each sample by the RMP of the NIST, 
allowing participating laboratories to evaluate the accuracy of their own results by comparing 
them to the NIST target values. As such, the target value may substitute the value as was to be 
obtained by analysis with the reference procedure. In addition to ‘Total 25OHD’ 
(25OHD3+25OHD2), DEQAS also conveys the NIST values for the individual metabolites, 
i.e., 25OHD3, 25OHD2 and 3-epi-25OHD3. 
Examination of DEQAS and HunMen samples 
In 2009–2010, the samples from the HunMen cohort were analyzed by HPLC using a 
Jasco HPLC system (Jasco, Tokyo, Japan) and Bio-Rad reagent kit (Bio-Rad Laboratories, 
Hercules, CA, USA). For the determination of 25OHD3 and 25OHD2 samples have to be 
prepared. The sample is purified by precipitation reagents from the proteins and interfering 
analytes, followed by separation of the metabolites (25OHD3, 25OHD2, internal standard) on 
reverse silica column. Quantitative determination of the separated 25OHD by UV absorption 
detection at 265 nm.  
In our routine diagnostic laboratory, due to the ever-increasing volume of the samples 
processed for 25OHD determination, we switched to the automated DiaSorin LIAISON
® 
CLIA platform in June of 2014. 
We reanalyzed samples belonging to the HunMen cohort using the automated 
DiaSorin LIAISON
® 
total 25OHD CLIA. Our laboratory participates in DEQAS and the 
timing of reanalysis, with the automated DiaSorin LIAISON
® 
25OHD CLIA platform, 
coincided with that of the October 2015 DEQAS samples’ measurement. Identical analytic 
8 
 
conditions, i.e., reagents with the same LOT number, were insured for both the HunMen 
sample reanalysis and the DEQAS sample measurements. Finally, the HunMen 25OHD 
values were corrected using the linear regression equation derived from the analysis of 
relationship between our Liaison measured total 25OHD values and the DEQAS NIST total 
target values for all five of the DEQAS samples. 
Bone density measurements 
Dual energy X-ray absorptiometry examination was performed at the University of 
Debrecen, Department of Obstetrics and Gynaecology, using the LUNAR Prodigy (GE-Lunar 
Corp., Madison,WI, USA) densitometer. BMD was measured at L1–L4 lumbar spine (LS) 
and femur neck (FN).  
Statistical analysis 
The results of this study were analyzed “post hoc”. Descriptive statistics are presented 
as mean, median, range and standard deviation (SD). Kolmogorov-Smirnov test was used for 
the evaluation of the normality of the data. Most parameters were non normally distributed, 
therefore analyses were performed by Mann–Whitney U test. The Spearman’s rho was 
calculated for correlation analysis. Associations were tested using linear regression analysis 
after log transformation of not normal variables. Additionally, to reduce the confounding 
effect of age, the median age was used to form two subgroups. 
A value of p < 0.05 was considered statistically significant. All analyses were 
performed with the SPSS Statistics software, version 19.0 (IBM Corps. Armonk, NY, USA). 
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RESULTS 
Subject characteristics 
In order to reduce the confounding effect of age, using the median age of 59 years, the 
study population was divided into a middle-aged (those ≤ 59 years of age, n =98) and an older 
(those > 59 years of age, n = 96) sub-group. Compared to the middle-aged (age: ≤ 59 years, n 
= 98), older men had significantly higher serum OPG and significantly lower RANKL levels 
and RANKL/OPG ratios. 
Assessment of factors influencing osteoprotegerin levels 
Serum OPG significantly correlated with age, cystatin C, E2 and FTI. Furthermore, 
Cystatin C correlated with age (Spearman’s rho = 0.377, p < 0.001), creatinine (Spearman’s 
rho = 0.487, p < 0.001), MDRD eGFR (Spearman’s rho=−0.524, p < 0.001), E2 (Spearman’s 
rho=0.222, p = 0.003), P1NP (Spearman’s rho=0.151, p = 0.040) and OPG (Spearman’s 
rho=0.298, p < 0.001). Although OPG did not correlate with serum creatinine or MDRD 
eGFR, it did show a significant correlation with cystatin C-eGFR, and cystatin C and 
creatinine-eGFR. Furthermore, only the older men showed significant correlation between 
serum OPG and cystatin C (r = 0.322, p = 0.002) and E2 (r = 0.211, p = 0.043). Compared to 
the middle-aged (age: ≤ 59 years, n = 98), older men had significantly higher serum OPG and 
significantly lower RANKL levels and RANKL/OPG ratios. The middle-aged individuals 
showed no significant correlation between serum OPG and sRANKL levels and the other 
studied parameters (age, BMI, LS BMD, FN BMD, PTH, 25OHD, OC, CTx, P1NP, cystatin 
C) The older men showed a significant correlation between serum OPG levels and cystatin C 
(ρ = 0.322, p = 0.002), and serum OPG levels and E2 (ρ = 0.211, p = 0.043). Multivariate 
linear regression analysis was carried out to determine the statistically significant predictors 
of serum OPG levels. Including age (standard regression coefficient (β) = 0.232, p = 0.002), 
cystatin C (standard regression coefficient (β) = 0.182, p = 0.015), FTI (standard regression 
coefficient (β) = - 0.178, p = 0.012) and E2 (standard regression coefficient (β) = 0.166, p = 
0.021) in a regression model showed that age, cystatin C, FTI and E2 were significant 
predictors of serum OPG levels. 
Including cystatin C and E2 in a regression model showed that cystatin C (standard 
regression coefficient (β) = 0.345; p = 0.002) was the only significant predictor of serum OPG 
levels in the older men. 
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There was no statistically significant difference in the group with non-detectable (< 
0.02 pmol/L, n = 74) sRANKL concentrations as compared to those with detectable (≥ 0.02 
pmol/L, n = 120) sRANKL concentrations in the studied parameters, except for LS (1.190 
(0.810-1.892) vs. 1.143 (0.749-1.855) gm/cm
2
; p = 0. 043) and FN (0.984 (0.646-1.281) vs. 
0.949 (0.602-1.331) gm/cm
2
; p = 0.049) BMD. As such, LS and FN BMD is significantly 
lower in those with undetectable sRANKL levels.  
There was no difference in OPG, sRANKL and sRANKL/OPG ratio upon comparing 
the vitamin D sufficient (25OHD ≥ 75 nmol/L) with the vitamin D insufficient (25OHD < 75 
nmol/L) individuals. 
Examination of DEQAS and HunMen samples 
All samples for the HunMen cohort were reevaluated using the LIAISON
® 
DiaSorin 
CLIA platform for measuring total 25OHD. The timing of these measurements coincided with 
that of the October 2015 DEQAS survey in order to external quality assurance, using samples 
481 to 485. Identical analytic conditions, i.e., reagents with the same LOT number, were 
insured for both the HunMen sample reanalysis and the DEQAS sample measurements. 
Finally, the HunMen 25OHD values were corrected using the linear regression equation (y = 
1,0582x + 6,169) derived from the analysis of relationship between our LIAISON measured 
total 25OHD values and the DEQAS NIST total target values for all five of the DEQAS 
samples. 
The mean total 25OHD value changed markedly, i.e., from 73 nmol/L, with the 
original HPLC methology, to 53 nmol/L as measured by the DiaSorin LIAISON
® 
25OHD 
total CLIA platform, and following NIST total target value bias standardization to 62 nmol/L. 
As such, the originally reported prevalence of hypovitaminosis D (<75 nmol/L), as measured 
by HPLC, increased significantly from 53 to 72%, following standardization of the DiaSorin 
platform measured values. As reported previously with the HPLC-measured values, on 
comparing the means in the different seasons, there was a statistically significant difference (p 
< 0.01) between the summer and the other seasons in both the DiaSorin measured and 
standardized 25OHD values. Furthermore, after standardization, the HunMen values have 
been found to be at par with values reported by others in Hungary. 
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DISCUSSION 
Assessment of factors influencing osteoprotegerin levels  
Our results demonstrate that serum OPG levels increase and sRANKL/OPG ratio 
decreases with age in healthy men over 50 years of age. With regards to the relationship of 
OPG with age, our findings are in tune with those reported by others. The positive correlation 
of OPG with age is the only finding showing consensus in the different studies to date. The 
only exception with this regards is the nonsignificant finding by Oh et al., where the lack of 
correlation may be due to the limited number of cases studied (n = 80) and a relatively lower 
age maximum of the study population. 
With regards to the correlation of OPG with BMD and biochemical markers of bone 
turnover, as per the results of the studies published to date, statistically significant positive, 
negative and non-significant was found. Our finding of non-significance only contributes to 
the need for further studies. Knowing that OPG messenger ribonucleic acid (mRNA) is 
expressed in a variety of tissues, including lung, kidney and heart, multiple tissues contribute 
together to circulating OPG, as such measurement of OPG levels in the bone 
microenvironment is most desirable. Our finding of statistically significant positive 
correlation between E2 with OPG, along with those reported by Schulz et al. and Indridason 
et al., supports the finding that E2 increases OPG mRNA steady state levels and protein 
production in a human estrogen-responsive osteoblastic cell line. Furthermore, Khosla et al. 
have demonstrated that estrogen treatment increases OPG levels in adult men. Our finding of 
negative correlation between testosterone and OPG supports two and disagrees with another 2 
previous studies. Nonetheless, the negative correlation supports the finding by Khosla et al. 
where it was demonstrated in vivo that testosterone therapy resulted in lower OPG levels.  
Our finding of non-correlation of age with sRANKL is in accordance with that 
reported earlier. Upon bivariate analysis we found no correlation between sRANKL and 
BMD, this finding is in agreement with that of Trofimov et al. and Oh et al., but in 
disagreement with the findings of Stern et al., who reported an inverse association between 
RANKL and BMD. Nonetheless, we observed statistically higher FN and LS BMD in those 
with detectable (higher) sRANKL levels, this finding, at least in part, may explain the low 
risk of non-traumatic fracture in participants in the highest tertile of RANKL in the study by 
Schett et al. It needs to be pointed out that Schett et al. found no relationship between 
sRANKL and bone ultrasound data and they did not carry out BMD measurements in their 
study population. Adding to the controversy is the finding by Jorgensen et al., where they 
found no difference in BMD between those with detectable versus non-detectable sRANKL 
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levels. Although the present generation of sRANKL immunoassays has a better lower 
detection limit than its predecessors, methodology with improved detection limits are most 
desired. Probably introduction of more sensitive immunoassays may help quantify 
undetectable sRANKL levels and perhaps may help explore relationships between those with 
low sRANKL and its known predictors. As far, the one study that studied the relationship of 
sRANKL/OPG ratio with age found no significance with this regards, in contrast to this our 
study reports a negative correlation between the ratio and age. This finding certainly needs 
validation by others. 
Although it is suggested that PTH has a suppressive effect on OPG production, the 
present study did not find any correlation between PTH and OPG. Our results are in 
agreement with those of Indridason et al. and in contrast to those of Szulc et al. and Kudlacek 
et al. In contrast to the finding that 1,25 dihydroxyvitamin D stimulates OPG production, in 
vivo studies in healthy men, including the present study, have not found any correlation 
between 25OHD, an index of body vitamin D status, and OPG. 
In summary, the non-agreement between findings from different studies may be 
explained, at least partially, by the different assay methodology, in some cases the use of 
frozen samples more than a decade old, the different recruitment criteria used in the selection 
of the cohort, the size of the study sample and perhaps the age composition of the cohorts 
studied. 
The role of decreased protein clearance as a potential cause of age-related OPG 
elevation has been considered in a few previous studies. Mazzioti et al.found a significant 
positive correlation between creatinine and OPG, and Samelson et al. found that with 
increasing quartiles of OPG the GFR decreased significantly. This finding is in contrast to the 
results of Szulc et al., where no correlation was found between OPG and creatinine. Our 
findings show that there is no correlation between OPG and eGFR, when the MDRD equation 
is used, but there is a significant negative correlation using the CKD-EPI cystatin C and the 
CKD creatinine-cystatin C equations. This finding may illustrate the importance of the type of 
equation used to calculate eGFR. Nonetheless, the combined creatinine-cystatin C equation is 
considered to perform better than equations based on either of these markers alone. We found 
a strong positive correlation between OPG and cystatin C. Our positive finding is in contrast 
to that of Indridason et al., where no such correlation was found. Although the assay 
methodology used by Indridason et al. is not the one used by us, this difference alone does not 
explain the difference in the observations of the two studies. Nonetheless, serum OPG has 
been shown to correlate positively in male patients with chronic renal failure. 
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Although the study participants were members of a well-defined healthy cohort 
randomly selected from the population, there are limitations to our study. The HunMen study 
was not designed primarily for the aim of this manuscript, and only 194 samples were 
available for serum OPG and sRANKL determination from a total of 206 participants. In 
addition, we were not in a position to study the effects of bioavailable (free) sex hormones on 
OPG, instead we used calculated free sex hormone indices to carry out the different statistical 
analysis. Although the mechanism of the effect, as a renal marker or inhibitor of 
osteoclastogenesis, of cystatin C on OPG levels cannot be elucidated by the findings of the 
present study, we have found that it is a significant predictor of serum OPG levels. These 
findings need verification and further studies are necessary. 
The present study demonstrated that in addition to age, the stronger predictor, other 
adjustable factors such as cystatin C, FTI and E2 were also significant predictors of OPG. 
Furthermore, the association between cystatin C and OPG was more evident with increased 
age.  
In conclusion, cystatin C is a significant predictor of OPG independently of age, FTI 
and E2. 
Standardizing 25-hydroxyvitamin D data from the HunMen study 
Standardization of 25-hydroxyvitamin D (25OHD) values is still a challenge. An 
overview of the VDSP, which is an international effort coordinated by the Office of Dietary 
Supplements, NIH, in collaboration with several agencies, institutes and universities, has been 
provided elsewhere. The initial focus of the VDSP is on standardizing the measurement of 
25OHD in national health and nutrition surveys around the world, and there are two basic 
protocols, one protocol for standardizing current and future 25OHD measurement procedures 
and another protocol for standardizing 25OHD values from past surveys or studies. 
Cashman and colleagues have standardized serum 25OHD values from the Irish 
National Adult NutritionSurvey conducted in 2008–2010 as suggested by the VDSP protocol 
executing reanalysis of historic samples with liquid chromatography tandem mass 
spectrometry (LC-MS/MS). Sempos and colleagues corrected historical vitamin D survey 
data, where it was assumed that standardization is impossible, using the bias from DEQAS 
ALTM pertaining to the period when the survey was done. Sarafin and colleagues 
standardizing 25-hydroxyvitamin D values from the Canadian Health Measures Survey. Here, 
standardization was accomplished by using a two-step procedure. First, serum samples 
corresponding to the original plasma samples were remeasured by using the currently 
available immunoassay method. Second, 50 serumsamples with known 25OHD values 
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assigned by the NIST and Ghent reference method laboratories were measured by using the 
currently available immunoassay method. Lately, Cashman and colleagues applied the VDSP 
protocol to standardize 25OHD values from four Nordic populations. A specifically selected 
subset of bio-banked serum samples from each of the studies was reanalyzed for 25OHD by 
LC-MS/MS and a calibration equation developed between old and new 25OHD data, and this 
equation was applied to the entire datasets from each study. 
The limitations of our study include the use of 6-year-old samples stored at −70 °C 
and an indirect approach. Validation of our method by assessing the accuracy of the 
calculation on additional serum samples is desirable. Perhaps not a limitation, but our 
approach would require constant monitoring of the bias from the NIST total target value in 
each DEQAS survey. As such, after each round of the DEQAS survey, the regression analysis 
needs to be repeated using the new values and applied to values generated till the results of 
the upcoming survey are available. 
It is not a trivial task in underprivileged settings to follow the VDSP guidelines as 
such. In Hungary, there is no known laboratory that measures serum 25OHD using the 
recommended reference measurement procedure in a routine laboratory setting or a research 
faculty. The financial burden involved in getting historic samples remeasured with LC-
MS/MS as such may be too arduous to handle. On the other hand, participation fee for the 
DEQAS program is quite reasonable and the NIST total target values communicated by the 
program may come in handy to allow correction of 25OHD values. Our simple approach 
towards standardizing 25OHD values using the DEQAS survey bias from NIST total target 
value may encourage participating laboratories to readily correct values at primary result 
delivery. We are suggesting an alternative to the VDSP requirement of the RMP in settings 
where the methodology or the financing of analysis is unavailable. We sincerely acknowledge 
the limitations of our approach but it may suffice where the VDSP protocol cannot be adhered 
to. Our approach may perhaps complement the VDSP protocol and offer an alternative until 
commercial assays are developed that yield values that are equal to the NIST concentration 
for any sample within certain prescribed error limits. 
In conclusion, a simple approach readily applicable at the point of conception of the 
25OHD values, i.e., at the routine diagnostic laboratory where the measurements are primarily 
done, could perhaps be a practical solution to the anomaly surrounding non-standardized 
25OHD values.  
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SUMMARY 
In addition to being a key regulator of osteoclastogenesis, the OPG/RANKL/RANK 
system is reported as being a significant mediator between factors such as estradiol, 
testosterone, parathyroid hormone, vitamin D, and bone turnover. Data on OPG and RANKL 
levels in healthy men is accumulating. Nonetheless, based on published data, it may well be 
generalized that the association between OPG/RANKL and its predictors is lacking 
consensus. Furthermore, the association of cystatin C with OPG and RANKL has only been 
limitedly investigated in the healthy, where no significant correlation was found.  
We determined serum OPG and sRANKL levels and examined its relationship with 
cystatin C, age, 25-hydroxyvitamin D, parathyroid hormone, biochemical markers of bone 
turnover, total 17β-estradiol, total testosterone and L1–L4 and femur neck BMD data 
available from 194 randomly selected ambulatory men belonging to the HunMen cohort. OPG 
correlated significantly with age, cystatin C, E2  and FTI. Compared to the middle-aged (age: 
≤ 59 years, n = 98), older men (age > 59 years, n = 96) had significantly higher serum OPG 
and lower sRANKL levels. The older men showed a significant correlation between serum 
OPG levels and cystatin C and E2. The results of this study demonstrated that in addition to 
age (which was the stronger predictor), other modifiable factors such as cystatin C, FTI and 
E2 were also significant predictors of OPG, and that the association between cystatin C and 
OPG was more evident with increased age (older age group). As such, cystatin C is a 
significant predictor of OPG independently of age, FTI and E2. 
Low 25-hydroxyvitamin D levels are associated with poor skeletal and extra-skeletal 
health. As such, development of robust healthcare policy to improve vitamin D sufficiency is 
critical and is primarily based on vitaminD data achieved from measurement of total 25OHD. 
Nonetheless, vitamin D sufficiency is estimated by determining 25-hydroxyvitamin D 
concentrations and although there is abundance of data on vitamin D levels, standardization of 
25OHD values is still a challenge. We propose standardization by correction of the measured 
25OHD values using the linear regression equation derived from the analysis of relationship 
between total 25OHD values measured by the methodology used by the laboratory and the 
NIST total target values (TV) reported by the DEQAS for all five of the DEQAS samples in a 
given survey. We applied our approach to standardize total 25OHD values of the HunMen 
cohort.  
We reanalyzed samples belonging to the HunMen cohort using the automated 
DiaSorin LIAISON
® 
total 25OHD chemiluminescence immunoassay. All samples for the 
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HunMen cohort were evaluated using the automated DiaSorin LIAISON
® 
total 25OHD CLIA. 
Our laboratory participates in DEQAS, the timing of these measurements coincided with that 
of the October 2015 DEQAS survey using samples 481 to 485. The HunMen 25OHD values 
were corrected using the linear regression equation derived from the analysis of relationship 
between our Liaison measured total 25OHD values and the DEQAS NIST total target values 
for all five of the DEQAS samples. The mean total 25OHD value changed markedly, i.e., 
from 73 nmol/L, with the original HPLC methology, to 53 nmol/L as measured by the 
DiaSorin LIAISON
® 
CLIA platform, and following NIST total target value bias 
standardization to 62 nmol/L. As such, the originally reported prevalence of hypovitaminosis 
D (<75 nmol/L), as measured by HPLC, increased significantly from 53 to 72%, following 
standardization of the DiaSorin platform measured values.  
In conclusion, a simple approach readily applicable at the point of conception of the 
25OHD values, at the routine diagnostic laboratory where the measurements are primarily 
done, could perhaps be a practical solution to the anomaly surrounding non-standardized 
25OHD values. 
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NEW SCIENTIFIC RESULTS AND THEIR CLINICAL RELEVANCE 
 Our results suggest that their is a significant positive correlation between age and 
serum OPG levels, and a negative correlation between age and the sRANKL/OPG 
ratio in the HunMen cohort. 
 In the HunMen cohort, besides age being the strongest predictor of change in OPG 
levels, cystatin C, FTI and E2 also proved to be statistically significant factors 
influencing OPG. 
 Our results suggest that there is no correlation between OPG and eGFR when using 
the MDRD formula, but there is a significant correlation between OPG and eGFR 
when using the CKD-EPI cystatin C and CKD creatinine – cystatin C formula. 
 There is a statistically significant increased LS and FN BMD in those individuals who 
presented with measureable sRANKL levels, i.e., sRANKL ≥ 0.02 pmol/L. 
 Contrary to literature findings, which suggest that 1,25(OH)2D-vitamin stimulates 
OPG production, we did not find any correlation between 25OHD and OPG levels. 
 Contrary to literature findings, which suggest that PTH has an inhibitory effect on 
OPG, we did not find any correlation between PTH and OPG levels. 
 Our approach to use DEQAS data to formulate a master equation can be readily 
applied to standardize routine laboratory generated 25OHD values using various 
methodology in a cost-effective manner.  
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